Black Diamond Therapeutics Inc (BDTX) concluded trading on Thursday at a closing price of $2.58, with 0.47 million shares of worth about $1.22 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 20.00% during that period and on July 03, 2025 the price saw a loss of about -0.77%. Currently the company’s common shares owned by public are about 56.68M shares, out of which, 43.28M shares are available for trading.
Stock saw a price change of 4.88% in past 5 days and over the past one month there was a price change of 3.20%. Year-to-date (YTD), BDTX shares are showing a performance of -45.11% which increased to 20.56% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.20 but also hit the highest price of $6.75 during that period. The average intraday trading volume for Black Diamond Therapeutics Inc shares is 1.21 million. The stock is currently trading 5.76% above its 20-day simple moving average (SMA20), while that difference is up 22.05% for SMA50 and it goes to 5.93% higher than SMA200.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) currently have 56.68M outstanding shares and institutions hold larger chunk of about 61.96% of that.
The stock has a current market capitalization of $146.71M and its 3Y-monthly beta is at 2.87. PE ratio of stock for trailing 12 months is 41.82, while it has posted earnings per share of $0.06 in the same period. Its PEG reads 7.74 and has Quick Ratio of 9.24 while making debt-to-equity ratio of 0.15. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BDTX, volatility over the week remained 7.49% while standing at 7.35% over the month.
Stock’s fiscal year EPS is expected to rise by 117.72% while it is estimated to decrease by -507.78% in next year. EPS is likely to grow at an annualized rate of 5.40% for next 5-years, compared to annual growth of -5.22% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on July 01, 2025 offering an Outperform rating for the stock and assigned a target price of $11 to it. Coverage by Raymond James stated Black Diamond Therapeutics Inc (BDTX) stock as an Outperform in their note to investors on July 31, 2024, suggesting a price target of $20 for the stock. On July 14, 2023, Piper Sandler Initiated their recommendations, while on June 30, 2023, Stifel Upgrade their ratings for the stock with a price target of $10. Stock get a Buy rating from H.C. Wainwright on June 28, 2023.
